ecancermedicalscience

Clinical Study

Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent

12 Oct 2016
Pan Pantziarka, Gauthier Bouche, Vidula Sukhatme, Lydie Meheus, Ilse Rooman, Vikas P Sukhatme

Propranolol (PRO) is a well-known and widely used non-selective beta-adrenergic receptor antagonist (beta-blocker), with a range of actions which are of interest in an oncological context. PRO displays effects on cellular proliferation and invasion, on the immune system, on the angiogenic cascade, and on tumour cell sensitivity to existing treatments. Both pre-clinical and clinical evidence of these effects, in multiple cancer types, is assessed and summarised and relevant mechanisms of action outlined. In particular there is evidence that PRO is effective at multiple points in the metastatic cascade, particularly in the context of the post-surgical wound response. Based on this evidence the case is made for further clinical investigation of the anticancer effects of PRO, particularly in combination with other agents. A number of trials are on-going, in different treatment settings for various cancers.

Article metrics: 15755 views
5621
10134

Related Articles

Omobolaji O Ayandipo, Gabriel O Ogun, Olalekan J Adepoju, Ebenezer O Fatunla, Adefemi O Afolabi, Peter C Osuala, Temidayo O Ogundiran
Aida Raigon Ponferrada, Jose Luis Guerrero Orriach, Alfredo Malo Manso, Enrique Sepúlveda Haro, Salvador Romero Molina, Ana Fontaneda Heredia, Manolo Baena Lopez, Jose Cruz Mañas
Daniela Speisky, Mariano Villarroel, Felix Vigovich, Alejandro Iotti, Teresa Adriana García, Luciana Bella Quero, Mariano Bregante, María Teresa García de Davila
Sanjit Kumar Agrawal, Sudip Ratna Shakya, Shashank Nigam, Abhishek Sharma, Soumitra S Datta, Rosina Ahmed